Protocol and Product Design for a Removable, Bio‑identical Enamel & Dentin Regenerating Filling (BPA‑free, No Aluminium)

Executive summary

This document outlines a safe, clinically realistic product concept and step‑by‑step protocol for a removable, temporary dental filling that (1) acts as a durable, foldable temporary restoration, (2) continuously delivers ions/biomolecules that encourage biomimetic remineralization of enamel and dentin, and (3) is removable for periodic clinical inspection, re‑sterilization/cleaning and replenishment. The design avoids aluminium‑containing cements and BPA plastics. It favors clinically tested bioactive components and modern peptide‑ and glass‑based remineralization approaches, and flags experimental or potentially unsafe ingredients (e.g., boric acid) for caution and further safety testing.

Intended use and clinical advantages

• Temporary/removable restoration for small–moderate carious lesions, post‑partial caries removal or between endodontic/pulp capping appointments.
• Maintains occlusion and function while providing a controlled environment that promotes enamel/dentin remineralization and inhibits bacterial recolonization.
• Removability allows monthly/biannual clinical inspection, refresh of bioactive components and validated office re‑sterilization/cleaning.

Design principles and mechanism of action

• Barrier + active core model: an external flexible, wear‑resistant BPA‑free polymer shell (foldable beads or thin molded liner) that mechanically seals the cavity and supports chewing; an internal interpenetrating bioactive gel/granular core that releases calcium, phosphate and silicate and presents peptide scaffolds to nucleate ordered hydroxyapatite.
• Bioactivity: bioactive glass (silica‑calcium‑phosphate systems) provides sustained ionic release (Ca2+, PO43−, SiO44−) to drive apatite nucleation; amorphous calcium phosphate (ACP) and/or nano‑hydroxyapatite supply labile calcium/phosphate; self‑assembling peptides (e.g., amelogenin‑mimetic or P11‑4‑type sequences) and a protein scaffold (keratin fragments/hydrogel — experimental) guide crystallite formation and organization toward an enamel/dentin‑like mineral.
• Controlled porosity & ion exchange: the internal matrix should be microporous enough to allow saliva exchange and ion flux but limit bacterial ingress.
• Antimicrobial control: low‑risk strategies such as xylitol, antimicrobial peptides, or short‑term chlorhexidine use at visits rather than long‑term toxicants. Avoid chronic exposure to boric acid without full toxicology data.

Recommended materials (preferred choices and safety notes)

• Outer shell: medical‑grade thermoplastic polyurethane (TPU) or PEEK/PMMA variants formulated for intraoral use. Must be BPA‑free, non‑leaching, foldable and re‑sterilizable or single‑use depending on clinical workflow.
• Bioactive core:
• Bioactive glass (45S5 or tailored silicate formulations optimized for sustained Ca/P release).
• Amorphous calcium phosphate (nano‑ACP) or nano‑hydroxyapatite as a fast calcium source.
• Self‑assembling peptide(s) that have preclinical/clinical evidence for enamel remineralization (e.g., P11‑4 class peptides or amelogenin derivatives) — include only peptides with safety data.
• Keratin fragment/scaffold: experimental. If used, only well‑characterized, purified keratin peptides with biocompatibility data; do not claim proven enamel production without rigorous evidence.
• Silica as filler and mechanical strengthener; use food/medical grade silica nanoparticles suitably surface‑treated for compatibility.
• Adhesion: a reversible, non‑permanent adhesive layer (mussel‑inspired catechol chemistries or medical grade temporary dental adhesives validated for removability) to maintain seal and allow planned removal.
• Antimicrobial agents: prefer agents with established intraoral safety (e.g., regulated chlorhexidine for short term professional application, xylitol, antimicrobial peptides). Avoid chronic use of boric acid inside the mouth until full toxicology and local safety studies are completed — boric acid can be toxic if systemically absorbed.
• Exclude: aluminium‑containing cements, BPA‑containing plastics, untested homeopathic or traditional agents presented as active without safety/efficacy evidence.

Proposed product concept (example name: BioFold‑Rem)

BioFold‑Rem is supplied as a kit per patient/cavity consisting of:

• A set of sterile, pre‑shaped foldable polymer beads/shell segments or thin liners sized for typical Class I/II/III cavities (sterile single‑use outer shells OR a small number of reusable shells validated for office re‑sterilization).
• Single‑dose sterile bioactive cartridges (paste or gel) containing bioactive glass nanoparticles, nano‑ACP and a pre‑validated peptide blend in a biocompatible hydrogel carrier. Cartridges are single‑use; the shell can be reused when validated.
• Small packets of a mild reversible adhesive and an office disinfectant/cleaning kit validated to the material.
• Instructions for placement, home care and professional re‑processing/removal intervals.

Clinical protocol — step‑by‑step (chairside)

1. Patient selection: suitable for patients with small‑to‑moderate caries lesions where a temporary restorative period is desired, or when staged caries removal / pulp therapy requires temporization. Exclude patients with known allergies to product components or high risk of aspiration/ingestion of removable parts.
2. Lesion preparation: remove soft carious dentin as clinically indicated, leave firm dentin at the pulpal floor where appropriate. Rinse and dry the cavity; do not desiccate (moist dentin supports remineralization).
3. Optional short‑acting antisepsis: a professional rinse or brief application of a validated antimicrobial (e.g., 0.12% chlorhexidine rinse) to reduce bacterial load; avoid repeated daily in long term.
4. Apply a thin layer of reversible adhesive to cavity margins per manufacturer instructions to create an initial seal.
5. Load the bioactive cartridge into the cavity core. Shape the bioactive paste to fill the bulk of the defect to just below occlusal level.
6. Cover with the foldable BPA‑free shell/liner and seat it into place, folding as needed to conform with cavity walls. Confirm occlusion and adjust.
7. Light‑cure if the adhesive system requires polymerization, using only systems validated with the shell material. Avoid adhesives or cures that generate excessive heat.
8. Provide patient with written home care instructions and a small take‑home disinfectant mouth rinse if indicated (e.g., xylitol rinse). Schedule follow‑up visits: 1 week (check comfort), 1 month (clinical check and optional refresh), then 3–6 months depending on progress.

Monitoring, removal, cleaning & replenishment schedule

• Home care: normal brushing with fluoride toothpaste, avoid hard foods in the treated area for 48–72 hours, and use the provided rinse if indicated. If shell is removable by patient (only in approved designs), instruct strict handling and daily rinsing after meals with water; do not attempt chemical sterilization at home unless clinically instructed.
• Office schedule (recommended conservative approach):
  • 1 week: comfort and seal check (may be remote/telephone).
  • 1 month: remove shell in office, inspect cavity, document progress. Re‑clean: ultrasonic/enzymatic cleaning of shell and validated chemical disinfection per manufacturer protocol. Re‑apply fresh bioactive cartridge and re‑seat if regeneration is progressing.
  • 3–6 months: full clinical evaluation. Replace shell or decommission if a permanent restoration is indicated.
  • Replace the removable system every 6–12 months or sooner if wear, breakdown of seal, or loss of bioactive efficacy is detected.
• Cleaning/sterilization: do NOT autoclave flexible polymer shells unless manufacturer validation exists. Use validated dental prosthesis disinfectants (follow manufacturer’s validated contact times) or low‑temperature sterilization like ethylene oxide for reusable components at central sterilization facilities. For single‑use shells, dispose after indicated usage period.

Preclinical and regulatory development pathway (high level)

1. Material selection and in‑vitro screening: cytotoxicity (ISO 10993‑5/10), genotoxicity, hemocompatibility as required; mechanical testing (compressive strength, wear resistance, fatigue), ion release profile and bioactivity in simulated body fluid (SBF) and artificial saliva.
2. In vitro remineralization: tests on extracted human teeth to quantify remineralization depth, mineral density (micro‑CT, transverse microradiography) and bonding to dentin/enamel.
3. Antimicrobial and biofilm testing: quantify bacterial colonization and biofilm formation vs. control temporary materials.
4. Animal studies: safety and efficacy (enamel/dentin regeneration markers, local tissue response) under GLP where mandated.
5. Human clinical trials: phased trials to demonstrate safety, clinical performance (seal durability, patient comfort), and efficacy in promoting remineralization compared to standard temporaries. Collect adverse events and systemic exposure data (if any components are novel biologics/peptides).
6. Regulatory submission: device classification depends on jurisdiction (likely Class II in the U.S. for a restorative device with active ingredients); compile ISO 10993 data, mechanical testing, clinical evidence, manufacturing controls, sterilization validation and labeling.

Testing acceptance criteria (examples)

• Apatite formation: consistent surface hydroxyapatite formation within weeks in SBF/artificial saliva assays.
• Mechanical durability: compressive and wear resistance comparable to common temporary restorative materials for the intended use period.
• Biocompatibility: no cytotoxicity or significant irritation in ISO tests; acceptable pulp response in animal/human studies when used as indicated.
• Seal integrity: leakage testing (dye or bacterial challenge) showing clinically acceptable seal for intended temporization interval.

Safety cautions and things to avoid

• Do not use boric acid as a chronic intraoral antimicrobial without full toxicology and safety data: boron compounds can have systemic toxicity and are restricted in certain populations.
• Witch hazel and other herbal astringents may be tolerable topically but are not substitutes for validated antimicrobial/control strategies; include only after safety and compatibility tests.
• Avoid untested gluten‑containing or allergenic protein scaffolds — screen keratin preparations for endotoxin, impurities and allergenicity.
• Do not recommend patient re‑sterilization at home using household chemicals or heat; only use office‑validated protocols.

Research priorities and recommended collaborators

• Materials scientists with dental biomaterials experience (bioactive glass and peptide scaffolds).
• Oral biologists and enamel/dentin regeneration experts (amelogenesis researchers, stem‑cell/dentinogenesis groups).
• CROs for ISO 10993 testing and GLP toxicology.
• Regulatory consultants experienced with FDA/CE dental device pathways.

Key takeaways

• A removable, bioactive temporary filling is feasible conceptually by combining a durable, BPA‑free foldable shell with a replaceable bioactive core (bioactive glass + calcium/phosphate + validated peptides + safe scaffold).
• Safety, validated cleaning/sterilization, and rigorous preclinical/clinical evidence are essential — do not adopt unproven agents (e.g., boric acid) without full toxicology and regulatory approval.
• Work with dental materials researchers, clinicians and regulatory experts and follow ISO/FDA pathways to move a concept to a clinically acceptable product.

If you want, I can:

• Draft a prioritized preclinical test plan (detailed assays and acceptance criteria) for the formulation you prefer.
• Sketch a candidate bill of materials with clinically available suppliers for bioactive glass, peptides and medical‑grade polymers.
• Summarize the most relevant published evidence (citations) on peptide‑guided enamel remineralization and bioactive glass performance.